Omalizumab Treatment in Patients with Severe Allergic Asthma
ISTANBUL MEDICAL JOURNAL, cilt.18, sa.3, ss.135-138, 2017 (ESCI)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 3
- Basım Tarihi: 2017
- Doi Numarası: 10.5152/imj.2017.93653
- Dergi Adı: ISTANBUL MEDICAL JOURNAL
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.135-138
- Anahtar Kelimeler: Asthma, omalizumab, severe allergic asthma, uncontrolled allergic asthma, QUALITY-OF-LIFE, REAL-LIFE, ANTIBODY OMALIZUMAB, MODERATE, TOLERABILITY, MALIGNANCY, EFFICACY, THERAPY, SAFETY
- Akdeniz Üniversitesi Adresli: Evet
Özet
Introduction: Omalizumab is a monoclonal antibody used for treating patients with severe allergic asthma. It has has been shown to be effective and is being increasingly used. This study aimed to evaluate the long-term efficacy and safety of omalizumab treatment in patients with severe allergic asthma.